Research Analysts’ Weekly Ratings Changes for Sutro Biopharma (STRO)

Sutro Biopharma (NASDAQ: STRO) recently received a number of ratings updates from brokerages and research firms:

• 3/28/2026 – Sutro Biopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/25/2026 – Sutro Biopharma was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/25/2026 – Sutro Biopharma had its price target raised by Deutsche Bank Aktiengesellschaft from $51.00 to $55.00. They now have a “buy” rating on the stock.
• 3/24/2026 – Sutro Biopharma was upgraded by Wells Fargo & Company from “equal weight” to “overweight”. They now have a $27.00 price target on the stock, up from $8.00.
• 3/24/2026 – Sutro Biopharma was upgraded by HC Wainwright from “neutral” to “buy”. They now have a $28.00 price target on the stock, up from $10.00.

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.